|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 76.09 EUR | -0.35% |
|
+0.40% | -8.37% |
| 11/07 | Sanofi Receives Fda Approval for Subcutaneous Sarclisa Escena Administered Via On-Body Injector | CI |
| 10/07 | Sanofi Wins US FDA Approval for Subcutaneous Sarclisa Escena in Multiple Myeloma | MT |
| Market Cap | 9.15TCr 10TCr 8.44TCr 7.79TCr 15TCr 9,97600Cr 15TCr 1,00800Cr 40TCr 4,91500Cr 39TCr 38TCr 16,89500Cr | P/E 2026 * |
11.5x | P/E 2027 * | 10.6x |
|---|---|---|---|---|---|
| Enterprise Value | 10TCr 12TCr 9.33TCr 8.61TCr 16TCr 11,02600Cr 17TCr 1,11400Cr 44TCr 5,43200Cr 43TCr 42TCr 18,67400Cr | EV / Sales 2026 * |
2.15x | EV / Sales 2027 * | 1.94x |
| Free-Float |
89% | Yield 2026 * |
5.58% | Yield 2027 * | 5.91% |
Last Transcript: Sanofi
| 1 day | -0.35% | ||
| 1 week | +0.40% | ||
| Current month | +1.14% | ||
| 1 month | -0.60% | ||
| 3 months | -5.07% | ||
| 6 months | -9.74% | ||
| Current year | -8.37% |
| 1 week | 74.49 |  | 77.1 |
| 1 month | 71.27 | | 78 |
| Current year | 71.27 | | 84.9 |
| 1 year | 71.27 | | 93 |
| 3 years | 71.27 | | 111 |
| 5 years | 71.27 | | 111 |
| 10 years | 63.15 | | 111 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 01/05/2026 | |
| Director of Finance/CFO | 64 | 01/04/2024 | |
Houman Ashrafian
CTO | Chief Tech/Sci/R&D Officer | 51 | 11/09/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 60 | 30/04/2019 | |
Rachel Duan
BRD | Director/Board Member | 57 | 28/04/2020 |
Lise Kingo
BRD | Director/Board Member | 64 | 28/04/2020 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.35% | +0.40% | - | - | 10TCr | |
| -2.33% | -2.09% | +49.88% | +170.51% | 1,06000Cr | |
| -0.82% | -2.30% | +63.79% | +62.00% | 62TCr | |
| -0.73% | -4.98% | +28.91% | +82.99% | 44TCr | |
| +0.33% | -1.17% | +31.07% | +27.09% | 33TCr | |
| -0.02% | -2.85% | +29.15% | +45.24% | 28TCr | |
| -3.89% | -11.22% | +22.81% | +27.30% | 27TCr | |
| +0.66% | -1.42% | -26.59% | -37.71% | 22TCr | |
| -0.06% | -2.88% | +23.07% | +62.33% | 20TCr | |
| -3.72% | -1.10% | +18.41% | +70.56% | 16TCr | |
| Average | -1.09% | -3.25% | +26.72% | +56.70% | 39.71TCr | |
| Weighted average by Cap. | -1.29% | -2.96% | +36.75% | +83.91% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 4.7TCr 5.37TCr 4.33TCr 4TCr 7.59TCr 5,11900Cr 7.72TCr 52TCr 20TCr 2,52200Cr 20TCr 20TCr 8,67000Cr | 5TCr 5.72TCr 4.62TCr 4.26TCr 8.09TCr 5,45600Cr 8.22TCr 55TCr 22TCr 2,68800Cr 21TCr 21TCr 9,24000Cr |
| Net income | 799.04Cr 913.5Cr 737.01Cr 680.7Cr 1.29TCr 87TCr 1.31TCr 8.81TCr 3.46TCr 43TCr 3.43TCr 3.36TCr 1,47600Cr | 890.27Cr 1.02TCr 821.17Cr 758.43Cr 1.44TCr 97TCr 1.46TCr 9.81TCr 3.85TCr 48TCr 3.82TCr 3.74TCr 1,64400Cr |
| Net Debt | 963.14Cr 1.1TCr 888.38Cr 820.5Cr 1.56TCr 1,05000Cr 1.58TCr 11TCr 4.17TCr 52TCr 4.13TCr 4.04TCr 1,77900Cr | 551.93Cr 631Cr 509.09Cr 470.2Cr 892.18Cr 60TCr 907.19Cr 6.08TCr 2.39TCr 30TCr 2.37TCr 2.32TCr 1,01900Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 10/26/10 | €76.09 | -0.35% | 1,260 |
| 09/26/09 | €76.36 | +1.39% | 2,849 |
| 08/26/08 | €75.31 | -0.80% | 413 |
| 07/26/07 | €75.92 | +1.85% | 3,450 |
| 06/26/06 | €74.54 | -1.65% | 5,934 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SAN Stock
- 1SAN Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
